Department of Neurosurgery, Mount Sinai Hospital, New York, NY, USA.
Johnson & Johnson Medical Devices, Franchise Health Economics & Market Access, Irvine, CA, USA.
J Comp Eff Res. 2021 Mar;10(4):295-305. doi: 10.2217/cer-2020-0202. Epub 2021 Feb 17.
To compare outcomes among patients undergoing endovascular treatment for unruptured intracranial aneurysm (UIA) with the Enterprise stent versus the Neuroform or Low-Profile Visualized Intraluminal Support (LVIS) stent. Patients undergoing endovascular procedure for UIA were classified into Enterprise stent and Neuroform or LVIS stent group. Groups were propensity-score matched and generalized estimating equations were used for outcomes assessment. There were no significant between-group differences in length of stay or mortality. The Enterprise group had significantly lower odds of UIA-related inpatient readmissions versus the Neuroform/LVIS group (odds ratio: 0.62; 95% CI: 0.42-0.91). Enterprise stent use was associated with significantly lower readmissions versus competitor stent, with no difference in other study outcomes.
比较颅内未破裂动脉瘤（UIA）患者行血管内治疗中使用 Enterprise 支架与 Neuroform 或 Low-Profile Visualized Intraluminal Support（LVIS）支架的结局。将接受血管内 UIA 治疗的患者分为 Enterprise 支架组和 Neuroform 或 LVIS 支架组。对两组进行倾向评分匹配，并使用广义估计方程评估结局。两组患者的住院时间或死亡率无显著差异。与 Neuroform/LVIS 组相比，Enterprise 组 UIA 相关再入院的可能性显著降低（比值比：0.62；95%CI：0.42-0.91）。与竞品支架相比，Enterprise 支架的使用与再入院率显著降低相关，其他研究结局无差异。
